Hagop Kantarjian, MD
Enriched profileProfessor and Chair, Department of Leukemia, Division of Cancer Medicine; Samsung Distinguished Leukemia Chair in Cancer Medicine · The University of Texas MD Anderson Cancer Center
Hagop Kantarjian is Professor and Chair, Department of Leukemia, Division of Cancer Medicine; Samsung Distinguished Leukemia Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 5,579 publications with 270,473 citations (h-index 233); ClinicalTrials.gov lists 24 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Hagop Kantarjian as a Highly Cited Researcher (Clinical Medicine, 2014-2016, 2018-2024).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Hagop M. Kantarjian, MD, is Professor and Chair, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 5,579 publications with 270,473 citations (h-index 233), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 22 companies, 4 NIH-funded awards (1992–2019).
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Acute Myeloid Leukemia Research
- 24 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 298 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 2,524.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →sciencedaily.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:
- Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
- Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 27 Aug 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20257 payments$30,337openpaymentsdata.cms.gov ↗
- Hikma Pharmaceuticals USAProgram year202511 payments$19,810openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20255 payments$11,575openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
74.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor36.2%Valacyclovir100%Part D≥22 patientsFluoroquinolone Antibacterial25.5%Levofloxacin100%Part D≥14 patientsCancer & immunology
25.5%Kinase inhibitor25.5%Bosulif69%Iclusig31%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 1992–2019 per NIH RePORTER. The latest:
Congress activity
Updated 27 Aug 2026
859 congress contributions (1996–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Allogeneic stem cell transplantation-related outcomes in myelodysplastic syndromes.
ASCO Annual Meeting
ASCO2025Co-author - CD123 expression and its correlation with mutation profile in acute myeloid leukemia.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.
American journal of hematology
Letter2026 - Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.
Blood cancer journal
Review2026 - Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.
Blood cancer discovery
Clinical Trial2026 - Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
Blood cancer journal
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/hagop-kantarjian-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Facebook
facebook.com/MDAnderson/videos/reflections-on-contributions-of-leukemia-specialist-dr-hagop-kantarjian/9307447635994656
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Facebook
facebook.com/OncLive/videos/watch-hagop-kantarjian-md-of-md-anderson-cancer-center-share-insights-from-the-p/600874906205605
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
Mentions by others
where others cite or feature them- X / Twitter
X/Twitter: @DrHKantarjian
- LinkedIn
LinkedIn: Leukemia Department - Hagop Kantarjian, M.D. - MD Anderson Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - X / Twitter
MD Anderson News (@MDAndersonNews) tweet celebrating Dr. Kantarjian's 2023 ASCO Karnofsky Award, tagging @DrHKantarjian
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2014201520162018201920202021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Non-resident fellow in health policy
Rice University Baker Institute for Public Policy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bakerinstitute.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center